Search

Your search keyword '"Towers, Greg J"' showing total 33 results
Start Over Author "Towers, Greg J" Publication Year Range Last 3 years
33 results on '"Towers, Greg J"'

2. Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19

Author

Varona, Jose F, Landete, Pedro, Lopez-Martin, Jose A, Estrada, Vicente, Paredes, Roger, Guisado-Vasco, Pablo, de Orueta, Lucia Fernandez, Torralba, Miguel, Fortun, Jesus, Vates, Roberto, Barberan, Jose, Clotet, Bonaventura, Ancochea, Julio, Carnevali, Daniel, Cabello, Noemi, Porras, Lourdes, Gijon, Paloma, Monereo, Alfonso, Abad, Daniel, Zuñiga, Sonia, Sola, Isabel, Rodon, Jordi, Vergara-Alert, Julia, Izquierdo-Useros, Nuria, Fudio, Salvador, Pontes, Maria Jose, de Rivas, Beatriz, de Velasco, Patricia Giron, Nieto, Antonio, Gomez, Javier, Aviles, Pablo, Lubomirov, Rubin, Belgrano, Alvaro, Sopesen, Belen, White, Kris M, Rosales, Romel, Yildiz, Soner, Reuschl, Ann-Kathrin, Thorne, Lucy G, Jolly, Clare, Towers, Greg J, Zuliani-Alvarez, Lorena, Bouhaddou, Mehdi, Obernier, Kirsten, McGovern, Briana L, Rodriguez, M Luis, Enjuanes, Luis, Fernandez-Sousa, Jose M, Krogan, Nevan J, Jimeno, Jose M, and Garcia-Sastre, Adolfo

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Infectious Diseases, Cancer, Lung, Clinical Trials and Supportive Activities, Patient Safety, Prevention, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Adult, Aged, COVID-19, Cell Line, Tumor, Depsipeptides, Drug Evaluation, Preclinical, Female, Hospitalization, Humans, Kaplan-Meier Estimate, Length of Stay, Male, Middle Aged, Neutropenia, Peptides, Cyclic, SARS-CoV-2, Treatment Outcome, Viral Load, COVID-19 Drug Treatment, Biological sciences, Biomedical and clinical sciences
Abstract

Plitidepsin, a marine-derived cyclic-peptide, inhibits SARS-CoV-2 replication at nanomolar concentrations by targeting the host protein eukaryotic translation elongation factor 1A. Here, we show that plitidepsin distributes preferentially to lung over plasma, with similar potency against across several SARS-CoV-2 variants in preclinical studies. Simultaneously, in this randomized, parallel, open-label, proof-of-concept study (NCT04382066) conducted in 10 Spanish hospitals between May and November 2020, 46 adult hospitalized patients with confirmed SARS-CoV-2 infection received either 1.5 mg (n = 15), 2.0 mg (n = 16), or 2.5 mg (n = 15) plitidepsin once daily for 3 d. The primary objective was safety; viral load kinetics, mortality, need for increased respiratory support, and dose selection were secondary end points. One patient withdrew consent before starting procedures; 45 initiated treatment; one withdrew because of hypersensitivity. Two Grade 3 treatment-related adverse events were observed (hypersensitivity and diarrhea). Treatment-related adverse events affecting more than 5% of patients were nausea (42.2%), vomiting (15.6%), and diarrhea (6.7%). Mean viral load reductions from baseline were 1.35, 2.35, 3.25, and 3.85 log10 at days 4, 7, 15, and 31. Nonmechanical invasive ventilation was required in 8 of 44 evaluable patients (16.0%); six patients required intensive care support (13.6%), and three patients (6.7%) died (COVID-19-related). Plitidepsin has a favorable safety profile in patients with COVID-19.

Published
2022

3. Evolution of enhanced innate immune evasion by SARS-CoV-2

Author

Thorne, Lucy G, Bouhaddou, Mehdi, Reuschl, Ann-Kathrin, Zuliani-Alvarez, Lorena, Polacco, Ben, Pelin, Adrian, Batra, Jyoti, Whelan, Matthew VX, Hosmillo, Myra, Fossati, Andrea, Ragazzini, Roberta, Jungreis, Irwin, Ummadi, Manisha, Rojc, Ajda, Turner, Jane, Bischof, Marie L, Obernier, Kirsten, Braberg, Hannes, Soucheray, Margaret, Richards, Alicia, Chen, Kuei-Ho, Harjai, Bhavya, Memon, Danish, Hiatt, Joseph, Rosales, Romel, McGovern, Briana L, Jahun, Aminu, Fabius, Jacqueline M, White, Kris, Goodfellow, Ian G, Takeuchi, Yasu, Bonfanti, Paola, Shokat, Kevan, Jura, Natalia, Verba, Klim, Noursadeghi, Mahdad, Beltrao, Pedro, Kellis, Manolis, Swaney, Danielle L, García-Sastre, Adolfo, Jolly, Clare, Towers, Greg J, and Krogan, Nevan J

Subjects
Biological Sciences, Bioinformatics and Computational Biology, Biomedical and Clinical Sciences, Immunology, Medical Microbiology, Genetics, Emerging Infectious Diseases, Infectious Diseases, Coronaviruses, 2.1 Biological and endogenous factors, Aetiology, Infection, COVID-19, Coronavirus Nucleocapsid Proteins, Evolution, Molecular, Humans, Immune Evasion, Immunity, Innate, Interferons, Mitochondrial Precursor Protein Import Complex Proteins, Phosphoproteins, Phosphorylation, Proteomics, RNA, Viral, RNA-Seq, SARS-CoV-2, General Science & Technology
Abstract

The emergence of SARS-CoV-2 variants of concern suggests viral adaptation to enhance human-to-human transmission1,2. Although much effort has focused on the characterization of changes in the spike protein in variants of concern, mutations outside of spike are likely to contribute to adaptation. Here, using unbiased abundance proteomics, phosphoproteomics, RNA sequencing and viral replication assays, we show that isolates of the Alpha (B.1.1.7) variant3 suppress innate immune responses in airway epithelial cells more effectively than first-wave isolates. We found that the Alpha variant has markedly increased subgenomic RNA and protein levels of the nucleocapsid protein (N), Orf9b and Orf6-all known innate immune antagonists. Expression of Orf9b alone suppressed the innate immune response through interaction with TOM70, a mitochondrial protein that is required for activation of the RNA-sensing adaptor MAVS. Moreover, the activity of Orf9b and its association with TOM70 was regulated by phosphorylation. We propose that more effective innate immune suppression, through enhanced expression of specific viral antagonist proteins, increases the likelihood of successful transmission of the Alpha variant, and may increase in vivo replication and duration of infection4. The importance of mutations outside the spike coding region in the adaptation of SARS-CoV-2 to humans is underscored by the observation that similar mutations exist in the N and Orf9b regulatory regions of the Delta and Omicron variants.

Published
2022

6. SARS-CoV-2 variants evolve convergent strategies to remodel the host response

Author

Bouhaddou, Mehdi, Reuschl, Ann-Kathrin, Polacco, Benjamin J., Thorne, Lucy G., Ummadi, Manisha R., Ye, Chengjin, Rosales, Romel, Pelin, Adrian, Batra, Jyoti, Jang, Gwendolyn M., Xu, Jiewei, Moen, Jack M., Richards, Alicia L., Zhou, Yuan, Harjai, Bhavya, Stevenson, Erica, Rojc, Ajda, Ragazzini, Roberta, Whelan, Matthew V.X., Furnon, Wilhelm, De Lorenzo, Giuditta, Cowton, Vanessa, Syed, Abdullah M., Ciling, Alison, Deutsch, Noa, Pirak, Daniel, Dowgier, Giulia, Mesner, Dejan, Turner, Jane L., McGovern, Briana L., Rodriguez, M. Luis, Leiva-Rebollo, Rocio, Dunham, Alistair S., Zhong, Xiaofang, Eckhardt, Manon, Fossati, Andrea, Liotta, Nicholas F., Kehrer, Thomas, Cupic, Anastasija, Rutkowska, Magdalena, Mena, Ignacio, Aslam, Sadaf, Hoffert, Alyssa, Foussard, Helene, Olwal, Charles Ochieng’, Huang, Weiqing, Zwaka, Thomas, Pham, John, Lyons, Molly, Donohue, Laura, Griffin, Aliesha, Nugent, Rebecca, Holden, Kevin, Deans, Robert, Aviles, Pablo, Lopez-Martin, Jose A., Jimeno, Jose M., Obernier, Kirsten, Fabius, Jacqueline M., Soucheray, Margaret, Hüttenhain, Ruth, Jungreis, Irwin, Kellis, Manolis, Echeverria, Ignacia, Verba, Kliment, Bonfanti, Paola, Beltrao, Pedro, Sharan, Roded, Doudna, Jennifer A., Martinez-Sobrido, Luis, Patel, Arvind H., Palmarini, Massimo, Miorin, Lisa, White, Kris, Swaney, Danielle L., Garcia-Sastre, Adolfo, Jolly, Clare, Zuliani-Alvarez, Lorena, Towers, Greg J., and Krogan, Nevan J.

Published
2023
Full Text
View/download PDF

7. Evasion of cGAS and TRIM5 defines pandemic HIV

Author

Zuliani-Alvarez, Lorena, Govasli, Morten L., Rasaiyaah, Jane, Monit, Chris, Perry, Stephen O., Sumner, Rebecca P., McAlpine-Scott, Simon, Dickson, Claire, Rifat Faysal, K. M., Hilditch, Laura, Miles, Richard J., Bibollet-Ruche, Frederic, Hahn, Beatrice H., Boecking, Till, Pinotsis, Nikos, James, Leo C., Jacques, David A., and Towers, Greg J.

Published
2022
Full Text
View/download PDF

9. Evolutionary remodelling of N‐terminal domain loops fine‐tunes SARS‐CoV‐2 spike

Author

Cantoni, Diego, Murray, Matthew J, Kalemera, Mphatso D, Dicken, Samuel J, Stejskal, Lenka, Brown, Georgina, Lytras, Spyros, Coey, Jonathon D, McKenna, James, Bridgett, Stephen, Simpson, David, Fairley, Derek, Thorne, Lucy G, Reuschl, Ann‐Kathrin, Forrest, Calum, Ganeshalingham, Maaroothen, Muir, Luke, Palor, Machaela, Jarvis, Lisa, Willett, Brian, Power, Ultan F, McCoy, Laura E, Jolly, Clare, Towers, Greg J, Doores, Katie J, Robertson, David L, Shepherd, Adrian J, Reeves, Matthew B, Bamford, Connor G G, and Grove, Joe

Published
2022
Full Text
View/download PDF

11. Art and science: not as different as you think

Author

Walter, John, Milne, Richard, and Towers, Greg J.

Abstract

Greg Towers, Professor of Molecular Virology at University College London, and John Walter, Artist, are interviewed by Professor Richard Milne, Head of Teaching in Infection and Immunity at University College London about their science and art collaboration.

Published
2024
Full Text
View/download PDF

12. Publisher Correction: Evolution of enhanced innate immune evasion by SARS-CoV-2

Author

Thorne, Lucy G., Bouhaddou, Mehdi, Reuschl, Ann-Kathrin, Zuliani-Alvarez, Lorena, Polacco, Ben, Pelin, Adrian, Batra, Jyoti, Whelan, Matthew V. X., Hosmillo, Myra, Fossati, Andrea, Ragazzini, Roberta, Jungreis, Irwin, Ummadi, Manisha, Rojc, Ajda, Turner, Jane, Bischof, Marie L., Obernier, Kirsten, Braberg, Hannes, Soucheray, Margaret, Richards, Alicia, Chen, Kuei-Ho, Harjai, Bhavya, Memon, Danish, Hiatt, Joseph, Rosales, Romel, McGovern, Briana L., Jahun, Aminu, Fabius, Jacqueline M., White, Kris, Goodfellow, Ian G., Takeuchi, Yasu, Bonfanti, Paola, Shokat, Kevan, Jura, Natalia, Verba, Klim, Noursadeghi, Mahdad, Beltrao, Pedro, Kellis, Manolis, Swaney, Danielle L., García-Sastre, Adolfo, Jolly, Clare, Towers, Greg J., and Krogan, Nevan J.

Published
2022
Full Text
View/download PDF

16. Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19

Author

Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Consejo Superior de Investigaciones Científicas (España), Grifols, YoMeCorono, National Institutes of Health (US), Roddenberry Foundation, Defense Advanced Research Projects Agency (US), Center for Research for Influenza Pathogenesis (US), National Institute of Allergy and Infectious Diseases (US), Swiss National Science Foundation, Varona, José F., Landete, Pedro, López-Martín, José A., Estrada, Vicente, Paredes, Roger, Guisado Vasco, P., Fernández de Orueta, Lucía, Torralba, Miguel, Fortún, Jesús, Vates, Roberto, Barberán, José, Clotet, Bonaventura, Ancochea, Julio, Carnevali, Daniel, Cabello, Noemí, Porras, Lourdes, Gijón, Paloma, Monereo, Alfonso, Abad, Daniel, Zúñiga Lucas, Sonia, Solá Gurpegui, Isabel, Rodón, Jordi, Vergara-Alert, Júlia, Izquierdo-Useros, Núria, Fudio, Salvador, Pontes, María José, Rivas, Beatriz de, Girón de Velasco, Patricia, Nieto, Antonio, Gómez, Javier, Avilés, Pablo, Lubomirov, Rubin, Belgrano, Álvaro, Sopesén, Belén, White, Kris M., Rosales, Romel, Yildiz, Soner, Reuschl, Ann-Kathrin; Thorne, Lucy G.; Jolly, Claire; Towers, Greg J.; Zuliani-Alvarez, Lorena; Bouhaddou, Mehdi; Obernier, Kirsten; Enjuanes Sánchez, Luis CSIC ORCID ; Fernández-Sousa, José M.; Plitidepsin – COVID - 19 Study Group; Krogan, Nevan J.; Jimeno, José M.; García-Sastre, Adolfo, Reuschl, Ann-Kathrin, Thorne, Lucy G., Jolly, Claire, Towers, Greg J., Zuliani-Alvarez, Lorena, Bouhaddou, Mehdi, Obernier, Kirsten, McGovern, Briana L., Rodríguez, M. Luis, Enjuanes Sánchez, Luis, Fernández-Sousa, José M., Krogan, Nevan J., Jimeno, José M., García-Sastre, Adolfo, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Consejo Superior de Investigaciones Científicas (España), Grifols, YoMeCorono, National Institutes of Health (US), Roddenberry Foundation, Defense Advanced Research Projects Agency (US), Center for Research for Influenza Pathogenesis (US), National Institute of Allergy and Infectious Diseases (US), Swiss National Science Foundation, Varona, José F., Landete, Pedro, López-Martín, José A., Estrada, Vicente, Paredes, Roger, Guisado Vasco, P., Fernández de Orueta, Lucía, Torralba, Miguel, Fortún, Jesús, Vates, Roberto, Barberán, José, Clotet, Bonaventura, Ancochea, Julio, Carnevali, Daniel, Cabello, Noemí, Porras, Lourdes, Gijón, Paloma, Monereo, Alfonso, Abad, Daniel, Zúñiga Lucas, Sonia, Solá Gurpegui, Isabel, Rodón, Jordi, Vergara-Alert, Júlia, Izquierdo-Useros, Núria, Fudio, Salvador, Pontes, María José, Rivas, Beatriz de, Girón de Velasco, Patricia, Nieto, Antonio, Gómez, Javier, Avilés, Pablo, Lubomirov, Rubin, Belgrano, Álvaro, Sopesén, Belén, White, Kris M., Rosales, Romel, Yildiz, Soner, Reuschl, Ann-Kathrin; Thorne, Lucy G.; Jolly, Claire; Towers, Greg J.; Zuliani-Alvarez, Lorena; Bouhaddou, Mehdi; Obernier, Kirsten; Enjuanes Sánchez, Luis CSIC ORCID ; Fernández-Sousa, José M.; Plitidepsin – COVID - 19 Study Group; Krogan, Nevan J.; Jimeno, José M.; García-Sastre, Adolfo, Reuschl, Ann-Kathrin, Thorne, Lucy G., Jolly, Claire, Towers, Greg J., Zuliani-Alvarez, Lorena, Bouhaddou, Mehdi, Obernier, Kirsten, McGovern, Briana L., Rodríguez, M. Luis, Enjuanes Sánchez, Luis, Fernández-Sousa, José M., Krogan, Nevan J., Jimeno, José M., and García-Sastre, Adolfo

Abstract

Plitidepsin, a marine-derived cyclic-peptide, inhibits SARS-CoV-2 replication at nanomolar concentrations by targeting the host protein eukaryotic translation elongation factor 1A. Here, we show that plitidepsin distributes preferentially to lung over plasma, with similar potency against across several SARS-CoV-2 variants in preclinical studies. Simultaneously, in this randomized, parallel, open-label, proof-of-concept study (NCT04382066) conducted in 10 Spanish hospitals between May and November 2020, 46 adult hospitalized patients with confirmed SARS-CoV-2 infection received either 1.5 mg (n = 15), 2.0 mg (n = 16), or 2.5 mg (n = 15) plitidepsin once daily for 3 d. The primary objective was safety; viral load kinetics, mortality, need for increased respiratory support, and dose selection were secondary end points. One patient withdrew consent before starting procedures; 45 initiated treatment; one withdrew because of hypersensitivity. Two Grade 3 treatment-related adverse events were observed (hypersensitivity and diarrhea). Treatment-related adverse events affecting more than 5% of patients were nausea (42.2%), vomiting (15.6%), and diarrhea (6.7%). Mean viral load reductions from baseline were 1.35, 2.35, 3.25, and 3.85 log10 at days 4, 7, 15, and 31. Nonmechanical invasive ventilation was required in 8 of 44 evaluable patients (16.0%); six patients required intensive care support (13.6%), and three patients (6.7%) died (COVID-19-related). Plitidepsin has a favorable safety profile in patients with COVID-19.

Published
2022

19. SARS-CoV-2 evolution influences GBP and IFITM sensitivity

Author

Mesner, Dejan, primary, Reuschl, Ann-Kathrin, additional, Whelan, Matthew V. X., additional, Bronzovich, Taylor, additional, Haider, Tafhima, additional, Thorne, Lucy G., additional, Ragazzini, Roberta, additional, Bonfanti, Paola, additional, Towers, Greg J., additional, and Jolly, Clare, additional

Published
2023
Full Text
View/download PDF

20. SARS-CoV-2 Variants Evolve Convergent Strategies to Remodel the Host Response

Author

Bouhaddou, Mehdi, primary, Reuschl, Ann-Kathrin, additional, Polacco, Benjamin J., additional, Thorne, Lucy G., additional, Ummadi, Manisha R., additional, Ye, Chengjin, additional, Rosales, Romel, additional, Pelin, Adrian, additional, Batra, Jyoti, additional, Jang, Gwendolyn, additional, Xu, Jiewei, additional, Moen, Jack M., additional, Richards, Alicia L., additional, Zhou, Yuan, additional, Harjai, Bhavya, additional, Stevenson, Erica, additional, Rojc, Ajda, additional, Ragazzini, Roberta, additional, Whelan, Matthew V.X., additional, Furnon, Wilhelm, additional, De Lorenzo, Giuditta, additional, Cowton, Vanessa, additional, Syed, Abdullah M., additional, Ciling, Alison, additional, Deutsch, Noa, additional, Pirak, Daniel, additional, Dowgier, Giulia, additional, Mesner, Dejan, additional, Turner, Jane L., additional, McGovern, Briana L., additional, Rodriguez, M. Luis, additional, Leiva-Rebollo, Rocio, additional, Dunham, Alistair S., additional, Zhong, Xiaofang, additional, Eckhardt, Manon, additional, Fossati, Andrea, additional, Liotta, Nicholas, additional, Kehrer, Thomas, additional, Cupic, Anastasija, additional, Rutkowska, Magda, additional, Mena, Nacho, additional, Aslam, Sadaf, additional, Hoffert, Alyssa, additional, Foussard, Helene, additional, Olwal, Charles, additional, Huang, Weiqing, additional, Zwaka, Thomas, additional, Pham, John, additional, Lyons, Molly, additional, Donahue, Laura, additional, Griffin, Aliesha, additional, Nugent, Rebecca, additional, Holden, Kevin, additional, Deans, Robert, additional, Aviles, Pablo, additional, López, José Antonio, additional, Jimeno Doñaque, José María, additional, Obernier, Kirsten, additional, Fabius, Jacqueline M., additional, Soucheray, Margaret, additional, Hüttenhain, Ruth, additional, Jungreis, Irwin, additional, Kellis, Manolis, additional, Echeverria, Ignacia, additional, Verba, Kliment, additional, Bonfanti, Paola, additional, Beltrao, Pedro, additional, Sharan, Roded, additional, Doudna, Jennifer A., additional, Martinez-Sobrido, Luis, additional, Patel, Arvind, additional, Palmarini, Massimo, additional, Miorin, Lisa, additional, White, Kris, additional, Swaney, Danielle L., additional, Garcia-Sastre, Adolfo, additional, Jolly, Clare, additional, Zuliani-Alvarez, Lorena, additional, Towers, Greg J., additional, and Krogan, Nevan J., additional

Published
2023
Full Text
View/download PDF

21. SARS-CoV-2 variant biology: immune escape, transmission and fitness

Author

Carabelli, Alessandro M, Peacock, Thomas P, Thorne, Lucy G, Harvey, William T, Hughes, Joseph, COVID-19 Genomics UK Consortium, Peacock, Sharon J, Barclay, Wendy S, De Silva, Thushan I, Towers, Greg J, Robertson, David L, Carabelli, Alessandro M [0000-0003-3625-4021], Harvey, William T [0000-0001-9529-1127], Hughes, Joseph [0000-0003-2556-2563], Peacock, Sharon J [0000-0002-1718-2782], Robertson, David L [0000-0001-6338-0221], and Apollo - University of Cambridge Repository

Subjects
SARS-CoV-2, Humans, COVID-19, Biology, Immunity, Innate
Abstract

In late 2020, after circulating for almost a year in the human population, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibited a major step change in its adaptation to humans. These highly mutated forms of SARS-CoV-2 had enhanced rates of transmission relative to previous variants and were termed 'variants of concern' (VOCs). Designated Alpha, Beta, Gamma, Delta and Omicron, the VOCs emerged independently from one another, and in turn each rapidly became dominant, regionally or globally, outcompeting previous variants. The success of each VOC relative to the previously dominant variant was enabled by altered intrinsic functional properties of the virus and, to various degrees, changes to virus antigenicity conferring the ability to evade a primed immune response. The increased virus fitness associated with VOCs is the result of a complex interplay of virus biology in the context of changing human immunity due to both vaccination and prior infection. In this Review, we summarize the literature on the relative transmissibility and antigenicity of SARS-CoV-2 variants, the role of mutations at the furin spike cleavage site and of non-spike proteins, the potential importance of recombination to virus success, and SARS-CoV-2 evolution in the context of T cells, innate immunity and population immunity. SARS-CoV-2 shows a complicated relationship among virus antigenicity, transmission and virulence, which has unpredictable implications for the future trajectory and disease burden of COVID-19.

Published
2023
Full Text
View/download PDF

22. Author response: Pharmacologic hyperstabilisation of the HIV-1 capsid lattice induces capsid failure

Author

Faysal, KM Rifat, primary, Walsh, James C, primary, Renner, Nadine, primary, Márquez, Chantal L, primary, Shah, Vaibhav B, additional, Tuckwell, Andrew J, additional, Christie, Michelle P, additional, Parker, Michael W, additional, Turville, Stuart G, additional, Towers, Greg J, additional, James, Leo C, additional, Jacques, David A, additional, and Böcking, Till, additional

Published
2022
Full Text
View/download PDF

23. Global landscape of the host response to SARS-CoV-2 variants reveals viral evolutionary trajectories

Author

Bouhaddou, Mehdi, primary, Reuschl, Ann-Kathrin, additional, Polacco, Benjamin J., additional, Thorne, Lucy G., additional, Ummadi, Manisha R., additional, Ye, Chengjin, additional, Rosales, Romel, additional, Pelin, Adrian, additional, Batra, Jyoti, additional, Jang, Gwendolyn M., additional, Xu, Jiewei, additional, Moen, Jack M., additional, Richards, Alicia, additional, Zhou, Yuan, additional, Harjai, Bhavya, additional, Stevenson, Erica, additional, Rojc, Ajda, additional, Ragazzini, Roberta, additional, Whelan, Matthew V.X., additional, Furnon, Wilhelm, additional, De Lorenzo, Giuditta, additional, Cowton, Vanessa, additional, Syed, Abdullah M., additional, Ciling, Alison, additional, Deutsch, Noa, additional, Pirak, Daniel, additional, Dowgier, Giulia, additional, Mesner, Dejan, additional, Turner, Jane L., additional, McGovern, Briana L., additional, Rodriguez, M. Luis, additional, Leiva-Rebollo, Rocio, additional, Dunham, Alistair S., additional, Zhong, Xiaofang, additional, Eckhardt, Manon, additional, Fossati, Andrea, additional, Liotta, Nicholas, additional, Kehrer, Thomas, additional, Cupic, Anastasija, additional, Rutkowska, Magda, additional, Mena, Nacho, additional, Aslam, Sadaf, additional, Hoffert, Alyssa, additional, Foussard, Helene, additional, Pham, John, additional, Lyons, Molly, additional, Donahue, Laura, additional, Griffin, Aliesha, additional, Nugent, Rebecca, additional, Holden, Kevin, additional, Deans, Robert, additional, Aviles, Pablo, additional, López-Martín, José Antonio, additional, Jimeno, Jose M., additional, Obernier, Kirsten, additional, Fabius, Jacqueline M., additional, Soucheray, Margaret, additional, Hüttenhain, Ruth, additional, Jungreis, Irwin, additional, Kellis, Manolis, additional, Echeverria, Ignacia, additional, Verba, Kliment, additional, Bonfanti, Paola, additional, Beltrao, Pedro, additional, Sharan, Roded, additional, Doudna, Jennifer A., additional, Martinez-Sobrido, Luis, additional, Patel, Arvind, additional, Palmarini, Massimo, additional, Miorin, Lisa, additional, White, Kris, additional, Swaney, Danielle L., additional, García-Sastre, Adolfo, additional, Jolly, Clare, additional, Zuliani-Alvarez, Lorena, additional, Towers, Greg J., additional, and Krogan, Nevan J., additional

Published
2022
Full Text
View/download PDF

24. Pharmacologic hyperstabilisation of the HIV-1 capsid lattice induces capsid failure

Author

Faysal, K.M. Rifat, primary, Renner, Nadine, additional, Marquez, Chantal L, additional, Shah, Vaibhav, additional, Tuckwell, Andrew J, additional, Christie, Michelle P, additional, Parker, Michael W, additional, Turville, Stuart Grant, additional, James, Leo, additional, Towers, Greg J, additional, Jacques, David A, additional, and Boecking, Till, additional

Published
2022
Full Text
View/download PDF

25. Evolution of enhanced innate immune suppression by SARS-CoV-2 Omicron subvariants

Author

Reuschl, Ann-Kathrin, primary, Thorne, Lucy G., additional, Whelan, Matthew V.X., additional, Ragazzini, Roberta, additional, Furnon, Wilhelm, additional, Cowton, Vanessa M., additional, de Lorenzo, Giuditta, additional, Mesner, Dejan, additional, Turner, Jane L. E., additional, Dowgier, Giulia, additional, Bogoda, Nathasha, additional, Bonfanti, Paola, additional, Palmarini, Massimo, additional, Patel, Arvind H., additional, Jolly, Clare, additional, and Towers, Greg. J., additional

Published
2022
Full Text
View/download PDF

27. Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19

Author

Varona, José F., Landete, Pedro, López-Martín, José A., Estrada, Vicente, Paredes, Roger, Guisado Vasco, P., Fernández de Orueta, Lucía, Torralba, Miguel, Fortún, Jesús, Vates, Roberto, Barberán, José, Clotet, Bonaventura, Ancochea, Julio, Carnevali, Daniel, Cabello, Noemí, Porras, Lourdes, Gijón, Paloma, Monereo, Alfonso, Abad, Daniel, Zúñiga Lucas, Sonia, Solá Gurpegui, Isabel, Rodón, Jordi, Vergara-Alert, Júlia, Izquierdo-Useros, Núria, Fudio, Salvador, Pontes, María José, Rivas, Beatriz de, Girón de Velasco, Patricia, Nieto, Antonio, Gómez, Javier, Avilés, Pablo, Lubomirov, Rubin, Belgrano, Álvaro, Sopesén, Belén, White, Kris M., Rosales, Romel, Yildiz, Soner, Reuschl, Ann-Kathrin, Thorne, Lucy G., Jolly, Claire, Towers, Greg J., Zuliani-Alvarez, Lorena, Bouhaddou, Mehdi, Obernier, Kirsten, Enjuanes Sánchez, Luis CSIC ORCID, Fernández-Sousa, José M., Plitidepsin – COVID - 19 Study Group, Krogan, Nevan J., Jimeno, José M., García-Sastre, Adolfo, McGovern, Briana L., Rodríguez, M. Luis, Enjuanes Sánchez, Luis, Producció Animal, Sanitat Animal, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Consejo Superior de Investigaciones Científicas (España), Grifols, YoMeCorono, National Institutes of Health (US), Roddenberry Foundation, Defense Advanced Research Projects Agency (US), Center for Research for Influenza Pathogenesis (US), National Institute of Allergy and Infectious Diseases (US), and Swiss National Science Foundation

Subjects
Adult, Male, Neutropenia, Health, Toxicology and Mutagenesis, Clinical Trials and Supportive Activities, Plant Science, Kaplan-Meier Estimate, Biochemistry, Genetics and Molecular Biology (miscellaneous), Cell Line, Clinical Research, Depsipeptides, Humans, Lung, Aged, Cancer, Cyclic, Tumor, Ecology, SARS-CoV-2, Prevention, COVID-19, Evaluation of treatments and therapeutic interventions, Length of Stay, Viral Load, Middle Aged, Preclinical, COVID-19 Drug Treatment, Hospitalization, Treatment Outcome, Infectious Diseases, Good Health and Well Being, 6.1 Pharmaceuticals, Drug Evaluation, Female, Patient Safety, Peptides
Abstract

Plitidepsin, a marine-derived cyclic-peptide, inhibits SARS-CoV-2 replication at nanomolar concentrations by targeting the host protein eukaryotic translation elongation factor 1A. Here, we show that plitidepsin distributes preferentially to lung over plasma, with similar potency against across several SARS-CoV-2 variants in preclinical studies. Simultaneously, in this randomized, parallel, open-label, proof-of-concept study (NCT04382066) conducted in 10 Spanish hospitals between May and November 2020, 46 adult hospitalized patients with confirmed SARS-CoV-2 infection received either 1.5 mg (n = 15), 2.0 mg (n = 16), or 2.5 mg (n = 15) plitidepsin once daily for 3 d. The primary objective was safety; viral load kinetics, mortality, need for increased respiratory support, and dose selection were secondary end points. One patient withdrew consent before starting procedures; 45 initiated treatment; one withdrew because of hypersensitivity. Two Grade 3 treatment-related adverse events were observed (hypersensitivity and diarrhea). Treatment-related adverse events affecting more than 5% of patients were nausea (42.2%), vomiting (15.6%), and diarrhea (6.7%). Mean viral load reductions from baseline were 1.35, 2.35, 3.25, and 3.85 log10 at days 4, 7, 15, and 31. Nonmechanical invasive ventilation was required in 8 of 44 evaluable patients (16.0%); six patients required intensive care support (13.6%), and three patients (6.7%) died (COVID-19-related). Plitidepsin has a favorable safety profile in patients with COVID-19., This work was supported by grants from the Government of Spain (PIE_INTRAMURAL_ LINEA 1 - 202020E079; PIE_INTRAMURAL_CSIC-202020E043). The research of CBIG consortium (constituted by IRTA-CReSA, BSC, & IrsiCaixa) is supported by Grifols pharmaceutical. We also acknowledge the crowdfunding initiative #Yomecorono (https://www.yomecorono.com). N Izquierdo-Useros has nonrestrictive funding from PharmaMar to study the antiviral effect of Plitidepsin. NJ Krogan was funded by grants from the National Institutes of Health (P50AI150476, U19AI135990, U19AI135972, R01AI143292, R01AI120694, and P01AI063302); by the Excellence in Research Award (ERA) from the Laboratory for Genomics Research (LGR), a collaboration between the University of California, San Francisco (UCSF), University of California, Berkley (UCB), and GlaxoSmithKline (GSK) (#133122P); by the Roddenberry Foundation, and gifts from QCRG philanthropic donors. This work was supported by the Defense Advanced Research Projects Agency (DARPA) under Cooperative Agreement #HR0011-19-2-0020. The views, opinions, and/or findings contained in this material are those of the authors and should not be interpreted as representing the official views or policies of the Department of Defense or the U.S. Government. This research was partly funded by Center for Research for Influenza Pathogenesis and Transmission (CRIPT), a National Institute of Allergy and Infectious Diseases (NIAID) supported Center of Excellence for Influenza Research and Response (CEIRS, contract # 75N93021C00014), by DARPA grant HR0011-19-2-0020, by supplements to NIAID grants U19AI142733, U19AI135972, and DoD grant W81XWH-20-1-0270, and by the generous support of the JPB Foundation, the Open Philanthropy Project (research grant 2020-215611 (5384)), and anonymous donors to A García-Sastre. S Yildiz received funding from a Swiss National Foundation Early Postdoc Mobility fellowship (P2GEP3_184202).

Published
2022

29. Macrophage activation of cGAS and TRIM5 distinguish pandemic and non-pandemic HIV

Author

Zuliani-Alvarez, Lorena, primary, Larsen, Morten, additional, Rasaiyaah, Jane, additional, Monit, Chris, additional, Perry, Stephen O, additional, Sumner, Rebecca, additional, McAlpine-Scott, Simon, additional, Dickson, Claire, additional, Rifat Faysal, K. M., additional, Hilditch, Laura, additional, Miles, Richard, additional, Bibollet-Ruche, Frederic, additional, Hahn, Beatrice H, additional, Bocking, Till, additional, Pinotsis, Nicos, additional, James, Leo C, additional, Jacques, David, additional, and Towers, Greg J, additional

Published
2022
Full Text
View/download PDF

30. Evolution of enhanced innate immune evasion by SARS-CoV-2

Author

Thorne, Lucy G., primary, Bouhaddou, Mehdi, additional, Reuschl, Ann-Kathrin, additional, Zuliani-Alvarez, Lorena, additional, Polacco, Ben, additional, Pelin, Adrian, additional, Batra, Jyoti, additional, Whelan, Matthew V. X., additional, Hosmillo, Myra, additional, Fossati, Andrea, additional, Ragazzini, Roberta, additional, Jungreis, Irwin, additional, Ummadi, Manisha, additional, Rojc, Ajda, additional, Turner, Jane, additional, Bischof, Marie L., additional, Obernier, Kirsten, additional, Braberg, Hannes, additional, Soucheray, Margaret, additional, Richards, Alicia, additional, Chen, Kuei-Ho, additional, Harjai, Bhavya, additional, Memon, Danish, additional, Hiatt, Joseph, additional, Rosales, Romel, additional, McGovern, Briana L., additional, Jahun, Aminu, additional, Fabius, Jacqueline M., additional, White, Kris, additional, Goodfellow, Ian G., additional, Takeuchi, Yasu, additional, Bonfanti, Paola, additional, Shokat, Kevan, additional, Jura, Natalia, additional, Verba, Klim, additional, Noursadeghi, Mahdad, additional, Beltrao, Pedro, additional, Kellis, Manolis, additional, Swaney, Danielle L., additional, García-Sastre, Adolfo, additional, Jolly, Clare, additional, Towers, Greg J., additional, and Krogan, Nevan J., additional

Published
2021
Full Text
View/download PDF

31. Delocalized quinolinium-macrocyclic peptides, an atypical chemotype for CNS penetration.

Author

Pingitore, Valeria, Pancholi, Jessica, Hornsby, Thomas W., Warne, Justin, Pryce, Gareth, McCormick, Laura J., Hill, Julia, Bhosale, Gauri, Jing Peng, Newton, Lydia S., Towers, Greg J., Coles, Simon J., Ah Wing Edith Chan, Duchen, Michael R., Szabadkai, Gyorgy, Baker, David, and Selwood, David L.

Subjects
*PEPTIDES, *DRUG accessibility, *X-ray crystallography, *CENTRAL nervous system, *DRUG target
Abstract

Macrocyclic drugs can address an increasing range of molecular targets but enabling central nervous system (CNS) access to these drugs has been viewed as an intractable problem. We designed and synthesized a series of quinolinium-modified cyclosporine derivatives targeted to the mitochondrial cyclophilin D protein. Modification of the cation to enable greater delocalization was confirmed by x-ray crystallography of the cations. Critically, greater delocalization improved brain concentrations. Assessment of the compounds in preclinical assays and for pharmacokinetics identified a molecule JP1-138 with at least 20 times the brain levels of a non-delocalized compound or those reported for cyclosporine. Levels were maintained over 24 hours together with low hERG potential. The paradigm outlined here could have widespread utility in the treatment of CNS diseases. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Evolution of enhanced innate immune evasion by SARS-CoV-2

Author

Lucy G. Thorne, Mehdi Bouhaddou, Ann-Kathrin Reuschl, Lorena Zuliani-Alvarez, Ben Polacco, Adrian Pelin, Jyoti Batra, Matthew V. X. Whelan, Myra Hosmillo, Andrea Fossati, Roberta Ragazzini, Irwin Jungreis, Manisha Ummadi, Ajda Rojc, Jane Turner, Marie L. Bischof, Kirsten Obernier, Hannes Braberg, Margaret Soucheray, Alicia Richards, Kuei-Ho Chen, Bhavya Harjai, Danish Memon, Joseph Hiatt, Romel Rosales, Briana L. McGovern, Aminu Jahun, Jacqueline M. Fabius, Kris White, Ian G. Goodfellow, Yasu Takeuchi, Paola Bonfanti, Kevan Shokat, Natalia Jura, Klim Verba, Mahdad Noursadeghi, Pedro Beltrao, Manolis Kellis, Danielle L. Swaney, Adolfo García-Sastre, Clare Jolly, Greg J. Towers, Nevan J. Krogan, Thorne, Lucy G [0000-0001-7358-6047], Polacco, Ben [0000-0003-1570-9234], Hosmillo, Myra [0000-0002-3514-7681], Fossati, Andrea [0000-0001-5170-4903], Ragazzini, Roberta [0000-0003-2186-293X], Jungreis, Irwin [0000-0002-3197-5367], Obernier, Kirsten [0000-0002-4025-1299], Braberg, Hannes [0000-0002-7070-2257], Chen, Kuei-Ho [0000-0001-6541-0578], Memon, Danish [0000-0002-1365-0710], McGovern, Briana L [0000-0002-0492-9904], Jahun, Aminu [0000-0002-4585-1701], White, Kris [0000-0003-0889-0506], Goodfellow, Ian [0000-0002-9483-510X], Bonfanti, Paola [0000-0001-9655-3766], Shokat, Kevan [0000-0001-8590-7741], Jura, Natalia [0000-0001-5129-641X], Verba, Klim [0000-0002-2238-8590], Noursadeghi, Mahdad [0000-0002-4774-0853], Kellis, Manolis [0000-0001-7113-9630], Swaney, Danielle L [0000-0001-6119-6084], García-Sastre, Adolfo [0000-0002-6551-1827], Jolly, Clare [0000-0002-4603-2281], Towers, Greg J [0000-0002-7707-0264], Krogan, Nevan J [0000-0003-4902-337X], Apollo - University of Cambridge Repository, and Goodfellow, Ian G [0000-0002-9483-510X]

Subjects
Proteomics, Evolution, General Science & Technology, Vaccine Related, Evolution, Molecular, Biodefense, Mitochondrial Precursor Protein Import Complex Proteins, Genetics, Innate, 2.1 Biological and endogenous factors, Coronavirus Nucleocapsid Proteins, Humans, Viral, RNA-Seq, Aetiology, Phosphorylation, Lung, 631/326/596/4130, Immune Evasion, Multidisciplinary, SARS-CoV-2, Prevention, Stem Cells, 82/58, Immunity, article, Molecular, COVID-19, Cell Biology, Phosphoproteins, Immunity, Innate, Infectious Diseases, Emerging Infectious Diseases, RNA, RNA, Viral, Interferons, 631/553, Infection, Developmental Biology
Abstract

The emergence of SARS-CoV-2 variants of concern suggests viral adaptation to enhance human-to-human transmission1,2. Although much effort has focused on the characterization of changes in the spike protein in variants of concern, mutations outside of spike are likely to contribute to adaptation. Here, using unbiased abundance proteomics, phosphoproteomics, RNA sequencing and viral replication assays, we show that isolates of the Alpha (B.1.1.7) variant3 suppress innate immune responses in airway epithelial cells more effectively than first-wave isolates. We found that the Alpha variant has markedly increased subgenomic RNA and protein levels of the nucleocapsid protein (N), Orf9b and Orf6—all known innate immune antagonists. Expression of Orf9b alone suppressed the innate immune response through interaction with TOM70, a mitochondrial protein that is required for activation of the RNA-sensing adaptor MAVS. Moreover, the activity of Orf9b and its association with TOM70 was regulated by phosphorylation. We propose that more effective innate immune suppression, through enhanced expression of specific viral antagonist proteins, increases the likelihood of successful transmission of the Alpha variant, and may increase in vivo replication and duration of infection4. The importance of mutations outside the spike coding region in the adaptation of SARS-CoV-2 to humans is underscored by the observation that similar mutations exist in the N and Orf9b regulatory regions of the Delta and Omicron variants., Nature, 602 (7897), ISSN:0028-0836, ISSN:1476-4687

Published
2022
Full Text
View/download PDF

33. Anti-type I interferon antibodies as a cause of severe COVID-19.

Author

Fajgenbaum DC, Hayday AC, Rogers AJ, Towers GJ, Wack A, and Zanoni I

Abstract

COVID-19 ranges from asymptomatic through to respiratory failure and death. Although specific pre-existing conditions such as age and male sex have been associated with poor outcomes, we remain largely ignorant of the mechanisms predisposing to severe disease. In this study, the authors discovered that approximately 10% of 987 patients with life-threatening COVID-19 harbored neutralizing antibodies to Type I interferons (IFNs) 1 . They demonstrated that these antibodies could neutralize high concentrations of the corresponding IFN and could rescue SARS-CoV-2 infection from inhibition by IFN in vitro . Importantly, anti-IFN antibodies were associated with low levels of serum IFN. These observations suggest that disease severity in these individuals results from a failure to control SARS-CoV-2 replication because of antibody-mediated IFN inhibition. The study suggests specific treatments and diagnostics for this class of severe COVID-19., Competing Interests: Adrian Hayday is a co-author and/or ongoing collaborator with Kai Kisand and Pärt Peterson, authors who contributed to the evaluated paper. He is also a Board Member and equity holder in ImmunoQure AG, a company that has identified naturally occurring human anti-cytokine antibodies targeting Type I interferon for potential use in the clinic., (Copyright: © 2022 Faculty Opinions Ltd.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results